Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?

Area of Science:

• Oncology Drug Development
• Clinical Trial Design
• Biostatistics

Background:

• Optimal oncology drug dosing is critical due to high anticancer agent toxicity.
• The "more is better" approach is challenged by targeted therapies and immunotherapies.
• The U.S. Food and Drug Administration (FDA) initiated Project Optimus to enhance patient-centered dosage optimization.

Purpose of the Study:

• To investigate current practices and challenges in oncology drug dosage optimization.
• To understand how industry sponsors are implementing FDA guidance on dosage optimization.
• To identify key areas for improvement in early-phase oncology trial design and execution.

Main Methods:

• An industry-wide survey was conducted among oncology statisticians in biopharmaceutical companies.
• The survey focused on current approaches to dosage selection and optimization in oncology drug development.
• Data analysis aimed to identify trends and challenges in translating regulatory recommendations into practice.

Main Results:

• A significant shift was observed away from solely relying on the maximum tolerated dose (MTD).
• Integrated strategies balancing efficacy, safety, pharmacokinetics, and patient experience are increasingly adopted.
• Challenges persist in applying FDA guidance due to developmental complexities and early-phase trial limitations.

Conclusions:

• Cross-functional collaboration between statisticians and other team members is essential for early-phase trials.
• Adoption of innovative trial designs can improve dosage optimization strategies.
• Proactive regulatory engagement is recommended for successful oncology drug development and dosage optimization.